BIIB - Biogen Inc.
Stock Analysis
Data: 2025-12-10us_universe.csv
- 2025IPOs.csv
- tb_sch.csv
- test_small.csv
- us_AI.csv
- us_cpu.csv
- us_Nuclear.csv
- us_penny_100.csv
- us_penny.csv
- us_Quantum.csv
- us_universe.csv
Last updated: Dec 10, 2025 at 6:03 PMFresh
show_chart Price & Trend 166.77 • 52W 110.04 - 167.87
Volume
Close
EMA9
MA50
MA150
MA200
Breakout
MA200 Reclaim
MA50 Touch
Pocket Pivot
PB Bounce
EMA9 Cross
auto_graph Pattern Recognition
info
info
Moderate pattern consistency: 57% win rate.
Signal Success Rate
57%
114 total signals
Avg Gain on Winners
+4.5%
65 wins
Avg Loss on Losers
-3.9%
49 losses
Recurring Behaviors
trending_up
Tendency to go on win streaks (longest: 14 signals in a row)
trending_down
Warning: Can experience losing streaks (longest: 8 signals)
Best Signal Type
MA50Touch
22 signals • 77% win rate
Avg gain: +3.7%
Worst Signal Type
MA200Reclaim
8 signals • 38% win rate
Avg loss: -0.6%
All Signal Types (Best ? Worst)
MA50Touch
77%
22 signals
+3.7%
PocketPivot
57%
51 signals
+1.2%
Breakout
50%
16 signals
-2.2%
PullbackBounce
47%
17 signals
+0.1%
MA200Reclaim
38%
8 signals
-0.6%
Trading Insights
lightbulb
Focus on MA50Touch signals - 77% win rate.
lightbulb
Avoid MA200Reclaim signals - only 38% successful.
Swing Cycle Analysis
Dominant pattern: ±5% every ~20.0 days (strength 0.25)
No consistent swing rhythm detected — observed ±5% fluctuations appear irregular or noise-driven.
Swing activity (±5% over ~20.0 days) is present but weak — downward / accumulation bias with more troughs than peaks; pattern confidence is low.
| Swing | Avg Days | Strength | Pattern? |
|---|---|---|---|
| 5% | 20.0 | 0.25 Weak+ | ? |
| 0% | 0.0 | 0.00 Weak | — |
? Trough
? Peak(turning points)
No consistent swing rhythm detected — observed ±5% fluctuations appear irregular or noise-driven.
assessment Key Metrics Universe Updated
Price
$166.77
Score
U
0.632
RS 6M
U
88
RS 3M
U
91
description Recommendation Summary
Hold
Confidence: 10/10
Performance: B+ Good
R/C: 0.69:1
HOLD (Confidence: 10/10) - Generic Momentum Setup | Early Uptrend (Above MA50) | Explosive Momentum (Elite) | R/R 0.69:1 (Risk 8.0%) | Avoid/Extended
Trend
Early Uptrend (Above MA50)
Momentum
Explosive Momentum (Elite)
Setup Type
Generic Momentum Setup
grade Absolute Rating
Strong Buy
Standalone Technical Quality
check_circle
Trend Strength (Price > MA50, proper stack) (1 points)
check_circle
13W Return ? +20% (2 points)
check_circle
4W Return ? +8% (1 points)
check_circle
Up/Down Volume ? 1.10 (1 points)
check_circle
ATR(20) ? 3.5% (1 points)
check_circle
Within 5%-25% of 52W High (1 points)
cancel
Risk/Reward ? 2:1 (R/R 0.69:1) (0 points)
Future Analytics
Coming soon...
security Risk Management
Suggested Stop Loss
$153.43
8.0% riskPotential Upside
+5.5%
R/R: 0.7:1Expected Move (20 d, ATR Proxy)
±$21.73 (13.0%)
Range: $145.04 - $188.50insights What It Means
The stock shows a mix of technical characteristics with strong relative strength and a solid composite score. Risk/Reward moderate (~0.7:1); catalysts or consolidation may improve it.
Positives
check_circle
Strong relative strength (RS6M 88, RS3M 91)
check_circle
Absolute rating Strong Buy
check_circle
Accumulation (Up/Down Vol 1.16)
Negatives / Risks
No major technical risksthumb_up Bullish Factors 7
check_circle
Elite 6m RS: 88th percentile (top 12%)
check_circle
Elite 3m RS: 91th percentile (top 9%)
check_circle
Accelerating momentum (3m > 6m RS)
check_circle
Price above all major MAs (strong trend)
check_circle
Strong 1-week gain: +7.2%
check_circle
Near 52-week high: -5.2% off peak
check_circle
Risk/Reward: 0.69:1 (Risk 8.0%, Reward 5.5% )
thumb_down Bearish Factors 1
cancel
Suboptimal R/R (<1:1)
analytics Technical Indicators
Current Price
$166.77
MA 50
$148.35
12.4%MA 150
$135.24
23.3%MA 200
$135.90
22.7%News & Sentiment
Last updated Dec 10 18:03
Sentiment line (?1..+1) with scaled article volume bars (height relative to sentiment range). Rolling 7d average smooths trend.
Positive day
Negative day
Neutral
Sentiment
7d Avg
Avg 7d: +0.05
Articles 7d: 24
Latest: -0.18 (9)Peak: -0.18 Dec 10
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating - GuruFocus
"BIIB stock" - Google News
Dec 10 12:35 PM
0.00
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating GuruFocus
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns - GuruFocus
"BIIB stock" - Google News
Dec 10 8:19 AM
0.00
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns GuruFocus
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha
"BIIB stock" - Google News
Dec 10 7:34 AM
0.00
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) Seeking Alpha
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
"BIIB stock" - Google News
Dec 10 5:44 AM
-0.30
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday Benzinga
New Analyst Forecast: $BIIB Given $143 Price Target - Quiver Quantitative
"BIIB stock" - Google News
Dec 10 4:20 AM
0.00
New Analyst Forecast: $BIIB Given $143 Price Target Quiver Quantitative
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News - GuruFocus
"BIIB stock" - Google News
Dec 10 4:05 AM
-0.10
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News GuruFocus
HSBC downgrades Biogen stock rating to Reduce on royalty concerns By Investing.com - Investing.com UK
"BIIB stock" - Google News
Dec 10 12:40 AM
-0.10
HSBC downgrades Biogen stock rating to Reduce on royalty concerns By Investing.com Investing.com UK
HSBC downgrades Biogen stock rating to Reduce on royalty concerns - Investing.com
"BIIB stock" - Google News
Dec 10 12:01 AM
-0.10
HSBC downgrades Biogen stock rating to Reduce on royalty concerns Investing.com
HSBC downgrades Biogen (BIIB)
BIIB stock - BingNews
Dec 09 8:03 PM
-0.10
Fintel reports that on December 10, 2025, HSBC downgraded their outlook for Biogen (NasdaqGS:BIIB) from Hold to Reduce. Analyst Price Forecast Suggests 3.20% Upside As of December 6, 2025, the average ...
Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive? - simplywall.st
"BIIB stock" - Google News
Dec 09 3:36 PM
+0.10
Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive? simplywall.st
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment - Quiver Quantitative
"BIIB stock" - Google News
Dec 08 3:40 PM
0.00
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment Quiver Quantitative
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome - simplywall.st
"BIIB stock" - Google News
Dec 08 1:37 PM
0.00
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome simplywall.st
1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds - The Globe and Mail
"BIIB stock" - Google News
Dec 08 2:08 AM
0.00
1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds The Globe and Mail
Is Biogen Stock Outperforming the Dow? - Barchart.com
"BIIB stock" - Google News
Dec 08 12:37 AM
+0.10
Is Biogen Stock Outperforming the Dow? Barchart.com
Is Biogen Stock Outperforming the Dow? - inkl
"BIIB stock" - Google News
Dec 08 12:37 AM
+0.10
Is Biogen Stock Outperforming the Dow? inkl
Is Biogen Stock Outperforming the Dow?
BIIB stock - BingNews
Dec 07 8:01 PM
+0.30
Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.
Stock Scanner
- scienceTestingkeyboard_arrow_down
Stock Scanner v1.0.0
Copyright Ⓒ 2025